Cre-inducible human CD59 mediates rapid cell ablation after intermedilysin administration.
Dechun Feng,Shen Dai,Fengming Liu,Yosuke Ohtake,Zhou Zhou,Hua Wang,Yonggang Zhang,Alison Kearns,Xiao Peng,Faliang Zhu,Umar Hayat,Man Li,Yong He,Mingjiang Xu,Chunling Zhao,Min Cheng,Lining Zhang,Hong Wang,Xiaofeng Yang,Cynthia Ju,Elizabeth C Bryda,Jennifer Gordon,Kamel Khalili,Wenhui Hu,Shuxin Li,Xuebin Qin,Bin Gao
DOI: https://doi.org/10.1172/JCI84921
IF: 19.456
2016-01-01
Journal of Clinical Investigation
Abstract:Cell ablation is a powerful tool for studying cell lineage and/or function; however, current cell-ablation models have limitations. Intermedilysin (ILY), a cytolytic pore-forming toxin that is secreted by Streptococcus intermedius, lyses human cells exclusively by binding to the human complement regulator CD59 (hCD59), but does not react with CD59 from nonprimates. Here, we took advantage of this feature of ILY and developed a model of conditional and targeted cell ablation by generating floxed STOP-CD59 knockin mice (ihCD59), in which expression of human CD59 only occurs after Cre-mediated recombination. The administration of ILY to ihCD59(+) mice crossed with various Cre-driver lines resulted in the rapid and specific ablation of immune, epithelial, or neural cells without off-target effects. ILY had a large pharmacological window, which allowed us to perform dose-dependent studies. Finally, the ILY/ihCD59-mediated cell-ablation method was tested in several disease models to study immune cell functionalities, hepatocyte and/or biliary epithelial damage and regeneration, and neural cell damage. Together, the results of this study demonstrate the utility of the ihCD59 mouse model for studying the effects of cell ablation in specific organ systems in a variety of developmental and disease states.